Loading...
Market
What will be Neuraceq's market penetration in Alzheimer's diagnostics by 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from reputable industry analysts
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Potentially $400 Million, to Enhance Neuraceq Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings, a diagnostic imaging company based in the U.S., has announced its acquisition of Germany-based Life Molecular Imaging for an upfront payment of $350 million, with potential additional milestones of up to $400 million. This acquisition aims to enhance Lantheus's capabilities in the Alzheimer's disease radiodiagnostic market, particularly through Life Molecular Imaging's Neuraceq, an F-18 PET imaging agent approved for detecting beta-amyloid plaques in patients being evaluated for Alzheimer's. The transaction is part of Lantheus's strategy to accelerate innovation in the growing market for Alzheimer's diagnostics.
View original story
Similar markets
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 40 • 25%
Less than 20 • 25%
20 to 30 • 25%
31 to 40 • 25%
More than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
10% to 20% • 25%
More than 30% • 25%
20% to 30% • 25%
Less than 10% • 25%
Rejected by FDA • 25%
FDA approved and in market • 25%
Withdrawn by manufacturer • 25%
Pending approval • 25%
20-30% • 25%
More than 30% • 25%
10-20% • 25%
Less than 10% • 25%
Decreases by more than 10% • 25%
Other • 25%
Remains within 10% of current share • 25%
Increases by more than 10% • 25%
No • 50%
Yes • 50%
More than 50% • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
Less than 20% • 25%
20% to 40% • 25%
More than 60% • 25%
40% to 60% • 25%
More than 60% • 25%
41% to 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
